New antibody AK1967 tested in healthy men as potential shock therapy

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Written informed consent to participate in this trial prior to any study-mandated procedure. * Male subjects aged 18 to 35 years inclusive. * Subjects have to agree to use a reliable way of contraception with their partners from study entry until one month after study drug administration. * BMI between 18 and 30 kg/m², with a lower limit of body weight of 50 kg and an upper limit of 100 kg. * Healthy as determined by medical history, physical examination, vital signs, 12-lead electrocardiogram, and clinical laboratory parameters. Exclusion Criteria: * Unwillingness to abstain from any medication, including recreational drugs or vitamin supplements during the course of the study and within two days prior to the treatment day. * Unwillingness to abstain from alcohol within one day prior to the treatment day until one day after the treatment day. * Surgery or trauma with significant blood loss or blood donation within one month prior to the treatment day. * History, signs or symptoms of cardiovascular disease, in particular: * History of frequent vasovagal collapse or of orthostatic hypotension * Resting pulse rate ≤45 or ≥100 beats/min * Hypertension (RR systolic \>160 or RR diastolic \>90 mmHg) * Hypotension (RR systolic \<100 or RR diastolic \<50 mmHg) * Conduction abnormalities on the ECG consisting of a 1st degree atrioventricular block or a complex bundle branch block * Any chronic cardiac arrhythmias (except PAC's, PVC's) * Renal impairment: plasma creatinine \>120 μmol/L * Liver function tests (alkaline phosphatase, AST, ALT and/or γ-GT) above 2x the upper limit of normal. * History of asthma * Atopic constitution * CRP above 2x the upper limit of normal, or clinically significant acute illness, including infections, within two weeks prior to the treatment day. * Treatment with investigational drugs or participation in any other clinical trial within 30 days prior to the treatment day. * Known or suspected of not being able to comply with the trial protocol. * Known hypersensitivity or allergic reactions to drug compounds, (i.e. previous adverse drug reactions). * Inability to personally provide written informed consent (e.g. for linguistic or mental reasons) and/or take part in the study.